Latest operating income for SRRA: $-100M.
Get informed when a big investor buys or sells
+ FollowAs of Mar 31, 2022
Trailing 12 months ending Mar 31, 2022
Sierra Oncology (SRRA) currently reports a operating income of $-100M as of March 2022. That compares with $-69M in the prior-year period — down 49.7% year over year. Use the charts on this page to explore Sierra Oncology's operating income history and peer comparisons.
Sierra Oncology's operating income decreased from $-69M to $-100M — a 49.7% year-over-year decrease (period ending March 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
Sierra Oncology reported $-100M in operating income as of March 2022. That compares with $-69M in the prior-year period — down 49.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current operating income of $-100M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Sierra Oncology, and consider following SRRA for alerts when major investors trade the stock.
Sierra Oncology is classified in the Healthcare sector. On operating income, it currently shows $-100M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing SRRA with unrelated industries.